English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Günther, S., Reinke, P. Y. A., Fernández-García, Y., Lieske, J., Lane, T. J., Ginn, H. M., et al. (2021). X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 372(6542), 642-646. doi:10.1126/science.abf7945.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
642.full.pdf (Publisher version), 2MB
Name:
642.full.pdf
Description:
This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
2021
Copyright Info:
© The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
:
suppl.zip (Supplementary material), 15MB
Name:
suppl.zip
Description:
SUPPLEMENT.pdf (Materials and Methods; Supplementary Text; Figs. S1 to S9; Tables S2, S5, and S6; References), TABLE S1.xlsx (Screened drug repurposing libraries. All tested compounds from the "Fraunhofer IME Repurposing Collection" and the "Safe-in-man" library, including information about tested crystals, obtained high-quality datasets and identified hits.), TABLE S4.xlsx (Summary of X-ray crystallographic data processing and refinement statistics), TABLE S7.xlsx (In silico screening of repurposing library against Mpro. The highest ranked 200 compounds of the virtual screening. The names and HYDE scores of the top ranked molecules are given. The yellow background highlights compounds for which high-quality X-ray data was obtained in the X-ray screening. The green background highlights compounds that were detected in the active site in the X-ray screen. Compounds highlighted in light green show a similar binding mode to the fragment with the PDB ligand ID K0G in complex with pro (PDB ID 5R83). Compounds highlighted in light yellow were reported as being active in other screening studies.), TABLE S3.xlsx (Comprehensive summary sheets of hit compounds. Summary showing electron-density maps, compound interactions with Mpro, detailed compound information, biochemical and cell-based antiviral reduction data.), MDAR REPRODUCIBILITY CHECKLIST.pdf
Visibility:
Public
MIME-Type / Checksum:
application/zip / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show
hide
Locator:
https://dx.doi.org/10.1126/science.abf7945 (Publisher version)
Description:
-
Description:
-

Creators

show
hide
 Creators:
Günther, S.1, Author
Reinke, P. Y. A.1, Author
Fernández-García, Y.1, Author
Lieske, J.1, Author
Lane, T. J.1, Author
Ginn, H. M.1, Author
Koua, F. H. M.1, Author
Ehrt, C.1, Author
Ewert, W.1, Author
Oberthuer, D.1, Author
Yefanov, O.1, Author
Meier, S.1, Author
Lorenzen, K.1, Author
Krichel, B.1, Author
Kopicki, J.-D.1, Author
Gelisio, L.1, Author
Brehm, W.1, Author
Dunkel, I.1, Author
Seychell, B.1, Author
Gieseler, H.1, Author
Norton-Baker, B.2, 3, Author              Escudero-Pérez, B.1, AuthorDomaracky, M.1, AuthorSaouane, S.1, AuthorTolstikova, A.1, AuthorWhite, T. A.1, AuthorHänle, A.1, AuthorGroessler, M.1, AuthorFleckenstein, H.1, AuthorTrost, F.1, AuthorGalchenkova, M.1, AuthorGevorkov, Y.1, AuthorLi, C.1, AuthorAwel, S.1, AuthorPeck, A.1, AuthorBarthelmess, M.1, AuthorSchlünzen, F.1, AuthorPaulraj, L. X.4, 5, AuthorWerner, N.1, AuthorAndaleeb, H.1, AuthorUllah, N.1, AuthorFalke, S.1, AuthorSrinivasan, V.1, AuthorFranca, B. A.1, AuthorSchwinzer, M.1, AuthorBrognaro, H.1, AuthorRogers, C.1, AuthorMelo, D.1, AuthorZaitsev-Doyle, J. J.1, AuthorKnoska, J.1, AuthorMurillo, G. E. P.1, AuthorMashhour, A. R.1, AuthorGuicking, F.1, AuthorHennicke, V.1, AuthorFischer, P.1, AuthorHakanpää, J.1, AuthorMeyer, J.1, AuthorGribbon, P.1, AuthorEllinger, B.1, AuthorKuzikov, M.1, AuthorWolf, M.1, AuthorBeccari, A. R.1, AuthorBourenkov, G.1, Authorvon Stetten, D.1, AuthorPompidor, G.1, AuthorBento, I.1, AuthorPanneerselvam, S.1, AuthorKarpics, I.1, AuthorSchneider, T. R.1, AuthorAlai, M. M. G.1, AuthorNiebling, S.1, AuthorGünther, C.1, AuthorSchmidt, C.1, AuthorSchubert, R.1, AuthorHan, H.1, AuthorBoger, J.1, AuthorMonteiro, D. C. F.1, AuthorZhang, L.1, AuthorSun, X.1, AuthorPletzer-Zelgert, J.1, AuthorWollenhaupt, J.1, AuthorFeiler, C. G.1, AuthorWeiss, M. S.1, AuthorSchulz, E.-C.2, Author              Mehrabi, P.2, Author              Karničar, K.1, AuthorUsenik, A.1, AuthorLoboda, J.1, AuthorTidow, H.1, AuthorChari, A.1, AuthorHilgenfeld, R.1, AuthorUetrecht, C.1, AuthorCox, R.1, AuthorZaliani, A.1, AuthorBeck, T.1, AuthorRarey, M.1, AuthorGünther, S.1, AuthorTurk, D.1, AuthorHinrichs, W.1, AuthorChapman, H. N.1, AuthorPearson, A .R.1, AuthorBetzel, C.1, AuthorMeents, A.1, Author more..
Affiliations:
1external, ou_persistent22              
2Miller Group, Atomically Resolved Dynamics Department, Max Planck Institute for the Structure and Dynamics of Matter, Max Planck Society, ou_1938288              
3Department of Chemistry, UC Irvine, ou_persistent22              
4Center for Free-Electron Laser Science, DESY, ou_persistent22              
5International Max Planck Research School for Ultrafast Imaging & Structural Dynamics (IMPRS-UFAST), Max Planck Institute for the Structure and Dynamics of Matter, Max Planck Society, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: The coronavirus disease (COVID-19) caused by SARS-CoV-2 is creating tremendous human suffering. To date, no effective drug is available to directly treat the disease. In a search for a drug against COVID-19, we have performed a high-throughput x-ray crystallographic screen of two repurposing drug libraries against the SARS-CoV-2 main protease (Mpro), which is essential for viral replication. In contrast to commonly applied x-ray fragment screening experiments with molecules of low complexity, our screen tested already-approved drugs and drugs in clinical trials. From the three-dimensional protein structures, we identified 37 compounds that bind to Mpro. In subsequent cell-based viral reduction assays, one peptidomimetic and six nonpeptidic compounds showed antiviral activity at nontoxic concentrations. We identified two allosteric binding sites representing attractive targets for drug development against SARS-CoV-2.

Details

show
hide
Language(s): eng - English
 Dates: 2020-11-202021-03-292021-04-022021-05-07
 Publication Status: Published in print
 Pages: 5
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: DOI: 10.1126/science.abf7945
 Degree: -

Event

show

Legal Case

show

Project information

show hide
Project name : -
Grant ID : 101003551
Funding program : Horizon 2020 (H2020)
Funding organization : European Commission (EC)
Project name : -
Grant ID : 759661
Funding program : Horizon 2020 (H2020)
Funding organization : European Commission (EC)

Source 1

show
hide
Title: Science
  Abbreviation : Science
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Washington, D.C. : American Association for the Advancement of Science
Pages: - Volume / Issue: 372 (6542) Sequence Number: - Start / End Page: 642 - 646 Identifier: ISSN: 0036-8075
CoNE: https://pure.mpg.de/cone/journals/resource/991042748276600_1